[{"Assets_0_Q1_USD":13979400000.0,"CommonStockDividendsPerShareDeclared_1_Q1_USD":0.16,"CommonStockSharesConverted_0_Q1_shares":143400000.0,"EarningsPerShareBasic_1_Q1_USD":0.5,"EarningsPerShareDiluted_1_Q1_USD":0.5,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":194500000.0,"NetIncomeLossConverted_1_Q1_USD":71600000.0,"RevenuesConverted_1_Q1_USD":1194000000.0,"StockholdersEquity_0_Q1_USD":6067800000.0,"StockholdersEquityConverted_0_Q1_USD":6067300000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":143600000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":143400000.0,"Ticker":"PRGO","CIK":"1585364","name":"PERRIGO CO PLC","OfficialName":"Perrigo Company plc Ordinary Shares","form":"10-Q","period":"20170331","fy":"2017.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"4754722726.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20170530"}]